SLE (mean±SD) | SLE HTN (mean±SD) | SLE LN HTN (mean±SD) | ||||
Inactive | Active | Inactive | Active | Inactive | Active | |
SLEDAI | 2.0±2.0 | 9.0±1.4 | 2.0±2.8 | 10.4±1.5 | 0.6±1.1 | 8.0±2.0 |
Anti-dsDNA antibody | 15±18 | 66±131 | 44±88 | 43±88 | 14±15 | 17±25 |
Urine protein/creatinine ratio | 0.08±0.02 | 0.16±0.15 | 0.16±0.16 | 0.18±0.09 | 0.27±0.17 | 3.36±4.35 |
C3 complement (mg/dL) | 102±20 | 100±42 | 114±14 | 106±7 | 114±2 | 105±23 |
C4 complement (mg/dL±SD) | 15±10 | 12±7 | 20±11 | 18±14 | 22±9 | 25±9 |
Antiphospholipid syndrome (% of total patients) | 0% | 0% | 20% | 20% | 0% | 0% |
Systolic blood pressure (mm Hg) | 117±11 | 120±9 | 140±21 | 154±20 | 112±12 | 122±18 |
Diastolic blood pressure (mm Hg) | 73±8 | 75±11 | 88±21 | 97±21 | 75±5 | 74±13 |
BMI | 30±15 | 31±15 | 29±7 | 29±7 | 31±6 | 30±5 |
Blood glucose (mg/dL) | 95±18 | 87±6 | 105±15 | 100±25 | 79±10 | 85±13 |
Total cholesterol (mg/dL) | 136±6 | 203±55 | 138±28 | 153±42 | 227±6 | 239±114 |
LDL (mg/dL) | 77±5 | 125±23 | 72±28 | 80±25 | 149±14 | 165±90 |
HDL (mg/dL) | 45±4 | 62±28 | 51±16 | 59±21 | 46±17 | 109±65 |
Triglycerides (mg/dL) | 71±10 | 76±23 | 74±32 | 77±25 | 109±65 | 141±38 |
BMI, body mass index; dsDNA, double stranded DNA; HDL, high-density lipoprotein; HTN, hypertension; LDL, low-density lipoprotein; LN, lupus nephritis; SLEDAI, SLE Disease Activity Index.